6c, g, k). addition, oligodendrocyte pathology was analyzed in early human being NMO lesions. Apart from early complement-mediated astrocyte damage, we observed a prominent, very early loss of oligodendrocytes and oligodendrocyte precursor cells (OPCs) as well as a delayed loss of myelin. Astrocyte repopulation of focal NMO lesions was already considerable after 1 week. Olig2-positive OPCs reappeared before NogoA-positive, adult oligodendrocytes. PK 44 phosphate Thus, using two experimental models that closely mimic the human being disease, our study demonstrates that oligodendrocyte and OPC loss is an extremely early feature in the formation of human being and experimental NMO lesions and prospects to subsequent, delayed demyelination, highlighting an important difference in the pathogenesis of MS and NMO. Keywords:Neuromyelitis optica, Demyelination, Oligodendrocyte death, Experimental autoimmune encephalomyelitis, Astrocyte == Intro == Neuromyelitis optica (NMO) is definitely a chronic inflammatory demyelinating disease that has long been regarded as a variant of multiple sclerosis (MS). Recently, antibodies against aquaporin-4 (AQP4) have been identified as a specific disease marker of NMO [12,13]. Pathologically, NMO is definitely characterized by harmful demyelinating lesions, i.e., lesions which are typically devoid of astrocytes as well mainly because myelin, and which display substantial axonal loss [16,17,23]. Probably the most characteristic feature of NMO, however, is the damage of astrocytes and their foot processes in early lesions, substantiating the cardinal part of astrocyte pathology in disease. Additional histological features that distinguish NMO from MS include perivascular immunoglobulin (Ig) and match deposition, vascular hyalinosis and the presence of polymorphonuclearand especially eosinophilicgranulocytes in the early inflammatory infiltrate [16,23,32]. Anti-AQP4 antibodies are found in the sera of around 75 % of NMO individuals, depending on the sensitivity of the assay applied [6,12,13,40,41]. Their titres have been shown to correlate loosely with disease severity and length of spinal cord involvement [9,22,37]. Intravenous transfer of recombinant monoclonal anti-AQP4 antibodies derived from a CSF plasma cell of an NMO patient induced astrocyte loss in an animal model of perivenous CNS swelling [1]. Similarly, the transfer TLR4 of sera derived from NMO individuals led to perivascular astrocyte loss in experimental autoimmune encephalomyelitis (EAE)-centered rodent models 3, 11], demonstrating the pathogenicity of anti-AQP4 antibodies in vivo. AQP4 is definitely a water channel expressed at particularly high denseness on astrocytic endfeet abutting the capillaries in specialized 3-dimensional constructions, so-called orthogonal arrays [5,28,43]. Large antigen densities are found in the optic nerves and spinal gray matter [32]. Besides mediating astrocyte loss, anti-AQP4 antibodies may downregulate AQP4 and excitatory amino acid transporter (EAAT)2 on astrocytic endfeet with ensuing astrocyte dysfunction [7]. NMO lesions closely resemble MS lesions, especially with regard to demyelination and the presence of foamy macrophages and lymphocytic swelling. However, in contrast to the majority of MS lesions, abundant apoptotic oligodendrocytes have been reported in and immediately adjacent to early NMO lesions [4,26]. Given that astrocytes are considered the main target in NMO, the time program and mechanisms of oligodendroglial and myelin damage are of particular interest. In addition, NMO lesions with different examples of astroglial repopulation have been described. Bipolar, presumably recently generated astrocytes are frequently found in early NMO lesions [26]. However, the time program and sequence of astrocytic restoration, oligodendroglial repopulation, and PK 44 phosphate remyelination have yet to be examined. In the present study, we employed two experimental models to examine the time course of myelin and oligodendroglial damage as well as oligodendroglial and astroglial repopulation in NMO-like lesions: (1) a transfer model of recombinant human anti-AQP4 antibodies (NMO rAb) into MBP (myelin-basic protein)-primed rats (NMO/EAE) [1]; and (2) a focal NMO model involving PK 44 phosphate the focal, intracerebral stereotactic injection of NMO rAb and human complement. The NMO/EAE and focal NMO models provide complementary data on NMO CNS injury in the presence and absence of a CNS-specific T-cell response and allow investigation of the temporal course of glial injury and recovery in experimental NMO lesions. == Materials and methods == == Human NMO tissue == CNS tissue from six patients with serologically confirmed NMO or NMO spectrum disease was included in our study (Table 1). 4/6 patients had undergone brain or spinal cord biopsy for diagnostic purposes to exclude tumor, lymphoma or infection. From two patients, we analyzed CNS tissue obtained at autopsy. Anti-AQP4 disease was neuropathologically confirmed by a focal loss of GFAP and AQP4 in macrophage-rich, inflammatory demyelinating lesions with relative axonal preservation. In addition to the diagnostic histological and immunohistochemical stainings applied, tissue sections were stained for NogoA and Olig2. The study was approved by the local ethics committee. == Table 1. == Clinical characteristics of patients with anti-AQP4-seropositive NMO or NMO spectrum disease who were included in the study All patients were seropositive for anti-AQP4 antibodies and harbored early lesions at biopsy or autopsy Aautopsy,Bbiopsy,ffemale,mmale,RRrelapsing-remitting == Animals == All experiments were.